Finerenone
Comparison with spironolactone in patients with CKD and T2D
BACKGROUND
Mineralocorticoid receptor antagonists (MRAs) are used clinically to manage chronic kidney disease (CKD), among other conditions. Mineralocorticoid receptor (MR) antagonism leads to reduced sodium reabsorption in the kidneys, increased potassium retention, and decreased fluid overload. It is hypothesized that directly targeting MR overactivation reduces inflammation and fibrosis in the heart, kidney and vasculature.1
Differences between steroidal and nonsteroidal MRAs have been described in terms of in-vitro potency and selectivity, relative tissue distribution, half-life, formation of active metabolites, MR binding characteristics, cofactor recruitment, and downstream gene expression. 1-6
Finerenone, a nonsteroidal MRA, demonstrates high potency and selectivity for the MR and has no relevant affinity for steroid hormone receptors (androgen, progesterone, estrogen, and glucocorticoid receptors). This selectivity is thought to enhance anti-inflammatory and antifibrotic effects, particularly in the kidney, heart, and blood vessels.1-3,6-8
CLINICAL DATA
Currently, no head-to-head, randomized phase 3 trials have directly compared the nonsteroidal MRA finerenone with the steroidal MRA spironolactone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Regarding real-world-data, a literature search retrieved the following retrospective, observational studies and metanalyses.
This page is intended for US healthcare professionals and may contain information outside of the approved prescribing information. It is provided in response to an unsolicited request. It is not intended as an endorsement of any usage not contained in the Prescribing Information. This response should be reviewed together with the current full Prescribing Information (including Boxed Warning) and Medical Safety Summary. These materials contain the approved indications, contraindications, warnings and precautions, adverse reactions, and other important safety information for Kerendia® (Finerenone).
Kerendia (finerenone) is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) indicated to: reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with Type 2 diabetes mellitus (T2DM); reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes mellitus (T1DM); reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%.
Retrospective trials
Idowu, et al (2025) conducted a retrospective propensity-matched cohort population analysis that compared hyperkalemia risk in adult patients (age ≥18 years) with CKD and T2D on finerenone versus spironolactone in a real-world setting. Patients were observed for up to one year for laboratory‑confirmed mild-moderate hyperkalemia (serum potassium >5.5 mmol/L) and severe hyperkalemia (serum potassium >6.5 mmol/L or hospitalization due to hyperkalemia). A total 3219 patients were matched into each cohort (finerenone and spironolactone group) and were followed for an average of 268 ± 123 days and 283 ± 125 days, respectively. In the matched cohort, the mean age was approximately 68 years, 60% had hypertension and 10% had heart failure.
- The incidence of mild-moderate hyperkalemia was 8.5% in the finerenone cohort versus 11.5% in the spironolactone group [RR 0.74, 95% confidence interval (CI) 0.64– 0.86, P < 0.001].
- The results were consistent across eGFR strata (eGFR <30: RR 0.78, 95% CI 0.63– 0.96, P = 0.017; and eGFR 30–60: RR 0.62, 95% CI 0.48–0.79, P < 0.001).
- There were no significant differences in the rates of severe hyperkalemia with 1.7% in the finerenone cohort vs 2.2% in the spironolactone arm (RR 0.79, 95% CI 0.55– 1.11, P = 0.175).
- Severe hyperkalemia rate was not reported in the eGFR ≥60 L/min/1.73 m2 subgroup to prevent patients’ re-identification (<10 patients had the outcome of interest).9
Wang, et al (2025) conducted a retrospective study using real-world data from the TriNetX network that compared the effectiveness and safety of finerenone (n=1132) and spironolactone (n=1132) in 2268 propensity score–matched (PSM) adults with CKD (eGFR 15–60 mL/min/1.73 m²) and T2D. After PSM, baseline characteristics were well balanced between the two groups. The mean age of patients from each group was 68.9 years. The primary outcomes were major adverse cardiovascular events (MACE), major adverse kidney events (MAKE), and all-cause mortality. The secondary outcome was hyperkalemia. Patients were followed from the index event to the earliest of: the outcome of interest, loss to followup, death, administrative censoring (14 March 2025), or 1.5 years.
- After a follow-up of 1.3 years (interquartile range, 0.8-1.5), MACE occurred in 112 patients (9.9%) in the finerenone group and 150 patients (13.3%) in the spironolactone group (adjusted hazard ratio [aHR], 0.74; 95% CI, 0.58–0.94; P=0.013), corresponding to an ARR of 3% (95% CI, 1%–6%) and a number needed to treat [NNT] of 29 (95% CI, 17– 143). This association remained consistent across individual components, including acute myocardial infarction, cardiac arrest/cardiogenic shock, and alternative MACE definitions.
- MAKE occurred in 46 patients (4.1%) in the finerenone group and 96 patients (8.5%) in the spironolactone group (aHR, 0.47; 95% CI, 0.33–0.67; P<0.001), corresponding to an ARR of 4% (95% CI, 2%–6%) and an NNT of 23 (95% CI, 16–42).
- A total of 35 patients (3.1%) in the finerenone group and 112 patients (9.9%) in the spironolactone group died (aHR, 0.31; 95% CI, 0.21–0.45; P<0.001), corresponding to an ARR of 7% (95% CI, 5%–9%) and an NNT of 15 (95% CI, 11–21).
- Patients on spironolactone experienced significantly more hyperkalemia episodes than patients on finerenone.
- Hyperkalemia (potassium ≥5.5 mmol/L) occurred in 26.4% of patients receiving spironolactone and 17.2% on finerenone (odds ratio [OR] 0.58; 95% CI, 0.47–0.71; P<0.001).
- Hyperkalemia (potassium ≥6.0 mmol/L) was observed in 10.2% of the spironolactone group and 5.9% of the finerenone group (OR 0.56; 95% CI, 0.41– 0.76; P<0.001).
- Severe hyperkalemia (potassium ≥6.5 mmol/L) occurred in 3.9% of patients in the spironolactone group and 2.1% in the finerenone group (OR 0.54; 95% CI, 0.32– 0.89; P=0.014).10
LITERATURE SEARCH
A literature search of Embase® , PubMed® , and/or other resources, including internal/external databases, was conducted pertaining to this topic on 19 May 2026.
REFERENCES
All references were accessed on the above literature search date.
- Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152–161. PMID: 33099609 https://www.ncbi.nlm.nih.gov/pubmed/33099609
- Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69–78. PMID: 24621652 https://www.ncbi.nlm.nih.gov/pubmed/24621652
- Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension. 2018;71(4):599–608. PMID: 29437893 https://www.ncbi.nlm.nih.gov/pubmed/29437893
- Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and Novel Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handb Exp Pharmacol. 2017;243:271– 305. PMID: 27830348 https://www.ncbi.nlm.nih.gov/pubmed/27830348
- Amazit L, Le Billan F, Kolkhof P, et al. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. J Biol Chem. 2015;290(36):21876–89. PMID: 26203193 https://www.ncbi.nlm.nih.gov/pubmed/26203193
- Barrera-Chimal J, Kolkhof P, Lima-Posada I, Joachim A, Rossignol P, Jaisser F. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. Expert Opin Investig Drugs. 2021;30(11):1141–1157. PMID: 34758679 https://www.ncbi.nlm.nih.gov/pubmed/34758679
- Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–63. PMID: 23713082 https://www.ncbi.nlm.nih.gov/pubmed/23713082
- Filippatos G, Anker SD, Bohm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105–14. PMID: 27130705 https://www.ncbi.nlm.nih.gov/pubmed/27130705
- Idowu A, Bryan Lo K, Adebolu O, et al. Hyperkalemia risk of finerenone versus spironolactone in CKD patients with type 2 diabetes. Nephrol Dial Transplant. 2025;40(10):1996–1999. PMID: 40440208 https://www.ncbi.nlm.nih.gov/pubmed/40440208
- Wang CA, Lai HW, Chen JY, et al. Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation. Nat Commun. 2025;16(1):9641. (including Supplementary appendix) PMID: 41173939 https://www.ncbi.nlm.nih.gov/pubmed/41173939